Pharmafile Logo

Genomics Ltd

- PMLiVE

Genomics extends drug discovery collaboration with Vertex

The new agreement builds on an existing collaboration between the companies

- PMLiVE

Nmblr launches the Align toolkit to transform collaboration into competitive advantage

Align, a new toolkit designed to help biopharma teams execute commercialisation strategies with greater efficiency, agility and lasting impact, has been unveiled today. Part of Nmblr, the strategy and collaboration...

Nmblr

- PMLiVE

Vertex’s triple combination cystic fibrosis therapy Alyftrek recommended by NICE

The rare inherited disease affects approximately 11,000 people in the UK

- PMLiVE

Vertex Pharmaceuticals’ cystic fibrosis therapy Alyftrek granted EC approval

The rare inherited disease affects more than 109,000 people worldwide

- PMLiVE

Being Rare Together: Medscape Education Sponsors the 2025 Cholestatic Liver Disease Summit

Medscape Education is a proud sponsor of the inaugural 2025 Cholestatic Liver Disease Summit, taking place June 26–28 in Aurora, Colorado, at the Hyatt Regency Aurora-Denver Conference Center. Hosted in...

Medscape Education

- PMLiVE

Vertex’s triple combination cystic fibrosis therapy Alyftrek approved by MHRA

Over 11,000 people in the UK are affected by the rare genetic disease

- PMLiVE

NICE approves Vertex’s Casgevy one-time gene therapy for sickle cell disease

About 15,000 people in England are living with the inherited blood disorder

Generative AI platforms drive drug discovery dealmaking

AI-Driven Platforms Enhance Drug Discovery Collaborations

Generative AI platforms are revolutionizing drug discovery, driving significant biopharma dealmaking by enabling the design of innovative small-molecule and biologic drug candidates.

Springer Nature

- PMLiVE

NICE recommends Vertex/CRISPR’s Casgevy gene therapy for beta thalassaemia

An estimated 460 patients in England with severe cases of the blood disorder could be eligible for Casgevy

- PMLiVE

Vertex and Orum partner on gene editing conditioning drugs in deal worth $945m

The agreement gives Vertex the rights to use Orum’s targeted protein degradation technology

- PMLiVE

Vertex and Genomics expand collaboration to accelerate precision medicines

The partners have been working together since 2018 to develop treatments for serious diseases

- PMLiVE

MIT researchers develop new algorithmic framework to identify molecules for drug discovery

SPARROW balances time and cost when optimising molecular candidates to streamline

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links